)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Inify Laboratories
Inify Laboratories (INIFY) investor relations material
Inify Laboratories Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary28 Oct, 2026
Executive summary
Q3 sales were SEK 5.2m, up 5% YoY; seasonal effects weighed on activity, while UK clinical diagnostics became operational and customer interest increased.
Growth has levelled off; ongoing customer projects are intended to support the next growth phase, with its timing the main uncertainty.
Financial highlights
Q3 operating income was SEK 5.238m vs SEK 4.991m; 9M income was SEK 19.168m vs SEK 15.772m.
Q3 operating loss was SEK 20.281m vs SEK 15.164m; 9M operating loss was SEK 64.196m vs SEK 48.662m.
Q3 net loss was SEK 19.669m vs SEK 14.645m; 9M net loss was SEK 62.979m vs SEK 47.202m.
Q3 EBITDA loss was SEK 16.674m vs SEK 13.827m; 9M EBITDA loss was SEK 52.910m vs SEK 44.948m.
Q3 external costs rose to SEK 9.7m from SEK 7.4m and personnel costs to SEK 11.4m from SEK 10.7m, reflecting UK establishment and expanded staffing.
Outlook and guidance
Sales growth has levelled off; several customer projects are underway, and the main uncertainty is when the next significant growth phase will begin.
Management expects UK hospital evaluations to progress toward procurement after successful evaluation; NHS processes involve multiple stakeholders and regional funding.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Inify Laboratories
- Sales rose 14% year-over-year as UK operations launched, but losses increased with expansion.INIFY
Q2 2026 - Q1 2026 sales up 17% year-over-year; UK expansion and new share issue drive future growth.INIFYQ1 2026
- Strong sales growth and UK expansion supported by a NOK 100 million share issue.INIFYQ4 2025
- Q3 2025 revenue up 76% year-over-year; UK lab on track; strong cash supports expansion.INIFYQ3 2025
- Strong sales growth and UK expansion mark Q2 2025, despite continued net losses.INIFYQ2 2025
- Q3 sales reached SEK 2.8M, with UK expansion and SEK 150M share issue planned.INIFYQ3 2024
- 62% revenue growth and positive subsidiary results mark a strong Q2 for Inify.INIFYQ2 2024
- Q1 2025 revenue up 130% year-over-year, fueled by Swedish growth and UK expansion.INIFYQ1 2025
- Strong revenue growth, UK expansion, and SEK 150M capital raise mark a transformative 2024.INIFYQ4 2024
Next Inify Laboratories earnings date
Q4 202624 Feb, 2027
Inify Laboratories
Next Inify Laboratories earnings date
Q4 202624 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Inify Laboratories specializes in cancer diagnostics, focusing primarily on pathology services. Leveraging advanced technology, the company employs a fully digital, standardized, and AI-supported workflow designed to enhance both the quality and efficiency of diagnostic processes, initially targeting prostate cancer diagnostics. This comprehensive service encompasses the entire sample handling process, including logistics, preparation, and reporting. The company is headquartered in Solna, Sweden, and its shares are listed on the Oslo Stock Exchange.